Business
Abeona Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Business Updates
On track to treat first RDEB patient in pivotal Phase 3 VIITAL™ study of EB-101 in Q1 2020 Positive interim data from MPS IIIA and MPS IIIB programs presented
About this update from Abeona Therapeutics Inc.
[{"type":"text","content":"On track to treat first RDEB patient in pivotal Phase 3 VIITAL™ study of EB-101 in Q1 2020\n Positive interim data from MPS IIIA and MPS IIIB programs presented at WORLDSymposium™; Completion of cohort 2 and first patient enrolled in cohort 3 of MPS IIIB study Issuance of U.S. Patents for AIM™ AAV capsids Closing of $103.5 million underwritten public offering Company to host investor conference call Tuesday, March 17 at 10:00 a.m. ET NEW YORK and CLEVELAND, March 16, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced fourth quarter and full year 2019 financial results, as well as business updates, which will be discussed on a conference call scheduled for Tuesday, March 17 at 10:00 a.m. ET. Interested parties are invited to participate in the call by dialing 844-369-8770 (domestic) or 862-298-0840 (international) or via webcast at https://www.webcaster4.com/Webcast/Page/1818/33644. “We have started 2020 strongly by opening enrollment in the pivotal Phase 3 VIITAL™ study evaluating EB-101 for RDEB and we remain on track to dose the first patient in the first quarter,” said João Siffert, M.D., Chief Executive Officer of Abeona. “A majority of study participants have been pre-screened and interest from the RDEB community has been high. The recently published long-term follow-up data leave us confident that VIITAL™ will demonstrate EB-101 has the unique potential to durably heal the most challenging large and chronic wounds faced by RDEB patients.” Dr. Siffert continued, “We have also made great strides in our MPS III gene therapy programs. Positive interim data from the ongoing Phase 1/2 Transpher A study demonstrated that ABO-102 preserved neurocognitive skills up to two years after treatment in MPS IIIA patients treated early in life. In MPS IIIB, dose-dependent and sustained reductions in disease-specific biomarkers demonstrated a clear biologic effect of ABO-101 treatment in the Phase 1/2 Transpher B study, which is now enrolling a third dose cohort. Finally, our $103.5 million gross underwritten public offering fully funds operations well into 2021 and enables the continued progress and momentum across our robust clinical pipeline.” Fourth Quarter and Recent HighlightsOpening of enrollment in the Phase 3 VIITAL™ study evaluating EB-101 for RDEB,...